Blinded Aliskiren Ali+Tab+CF


Combined with:

Aliskiren
Blinded Enalapril Comp-Ena+
Blinded NO Treatment Received Nomed
Comparator Enalapril

Indications and Reactions:

Role Indications Reactions
Primary
Cardiac Failure 80.8%
Cardiac Failure Congestive 4.8%
Cardiac Failure Chronic 2.8%
Diabetes Mellitus 2.4%
Hyperuricaemia 1.9%
Hypertension 1.2%
Hyperlipidaemia 0.9%
Atrial Fibrillation 0.8%
Back Pain 0.7%
Gastrooesophageal Reflux Disease 0.7%
Myocardial Infarction 0.5%
Congestive Cardiomyopathy 0.4%
Gastritis 0.4%
Prophylaxis 0.4%
Coronary Artery Disease 0.3%
Dyslipidaemia 0.3%
Hypercholesterolaemia 0.3%
Angina Pectoris 0.2%
Anticoagulant Therapy 0.2%
Blood Calcium Decreased 0.2%
Dyspnoea 9.8%
Vertigo 8.9%
Renal Impairment 8.1%
Ventricular Tachycardia 7.3%
Vomiting 7.3%
Renal Failure 6.5%
Weight Increased 6.5%
Pulmonary Oedema 5.7%
Orthopnoea 4.1%
Tachycardia 4.1%
Ventricular Dysfunction 4.1%
Cardiac Pacemaker Insertion 3.3%
Death 3.3%
Hyperkalaemia 3.3%
Pneumonia 3.3%
Sudden Death 3.3%
Therapeutic Agent Toxicity 3.3%
Upper Respiratory Tract Infection 3.3%
Disease Progression 2.4%
Dysfunctional Uterine Bleeding 2.4%
Secondary
Cardiac Failure 68.8%
Cardiac Failure Congestive 6.3%
Cardiac Failure Chronic 5.8%
Cardiac Failure Acute 3.0%
Diabetes Mellitus 3.0%
Atrial Fibrillation 2.5%
Hyperuricaemia 2.5%
Hypertension 1.5%
Myocardial Infarction 1.5%
Angina Pectoris 1.0%
Dyslipidaemia 1.0%
Cardiovascular Disorder 0.8%
Colitis Ulcerative 0.8%
Gastritis 0.5%
Arrhythmia 0.3%
Insomnia 0.3%
Keratoconjunctivitis Sicca 0.3%
Ventricular Extrasystoles 11.7%
Renal Impairment 10.0%
Ventricular Dysfunction 10.0%
Urine Output Decreased 8.3%
Coronary Artery Disease 6.7%
Scar 6.7%
Thrombosis 6.7%
Vertigo 5.0%
Coronary Artery Restenosis 3.3%
Disease Progression 3.3%
Heart Rate Decreased 3.3%
Left Ventricular Failure 3.3%
Pulmonary Oedema 3.3%
Renal Failure 3.3%
Thrombocytopenia 3.3%
Urinary Incontinence 3.3%
Vomiting 3.3%
Cardiac Failure 1.7%
Circulatory Collapse 1.7%
Death 1.7%

Drug Data